Phosphate binders for preventing and treating chronic kidney disease‐mineral and bone disorder (CKD‐MBD)

M Ruospo, SC Palmer, P Natale… - Cochrane Database …, 2018 - cochranelibrary.com
Background Phosphate binders are used to reduce positive phosphate balance and to lower
serum phosphate levels for people with chronic kidney disease (CKD) with the aim to …

[HTML][HTML] Management of hyperphosphatemia in end-stage renal disease: a new paradigm

A Rastogi, N Bhatt, S Rossetti, J Beto - Journal of Renal Nutrition, 2021 - Elsevier
Bone and mineral metabolism becomes dysregulated with progression of chronic kidney
disease (CKD), and increasing levels of parathyroid hormone serve as an adaptive …

Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis

R Brignardello-Petersen, A Bonner… - Journal of clinical …, 2018 - Elsevier
This article describes conceptual advances of the Grading of Recommendations
Assessment, Development, and Evaluation (GRADE) working group guidance to evaluate …

Mechanistic insights into CKD-MBD-related vascular calcification and its clinical implications

R Kaur, R Singh - Life Sciences, 2022 - Elsevier
Abstract Chronic Kidney Disease (CKD) is linked to a rising prevalence of morbidity and
mortality primarily from cardiovascular complications and is considered a high or very high …

Systematic review and meta-analyses of the effects of phosphate-lowering agents in nondialysis CKD

NM Lioufas, EM Pascoe, CM Hawley… - Journal of the …, 2022 - journals.lww.com
Background Benefits of phosphate-lowering interventions on clinical outcomes in patients
with CKD are unclear; systematic reviews have predominantly involved patients on dialysis …

Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide

M Cozzolino, A Galassi, F Conte… - … and clinical risk …, 2017 - Taylor & Francis
Secondary hyperparathyroidism (SHPT), a very frequent, severe, and worsening
complication of chronic kidney disease, is characterized by high serum parathyroid hormone …

Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta …

K Chaiyakittisopon, O Pattanaprateep… - The European Journal of …, 2021 - Springer
Background Uncontrolled hyperphosphatemia in chronic kidney disease (CKD) patients
commonly results in vascular calcification leading to increased risk of cardiovascular …

[HTML][HTML] Application of network meta-analysis in the field of physical activity and health promotion

X Su, DJ McDonough, H Chu, M Quan, Z Gao - Journal of Sport and Health …, 2020 - Elsevier
Continued advancement in the field of physical activity and health promotion relies heavily
on the synthesis of rigorous scientific evidence. As such, systematic reviews and meta …

[HTML][HTML] Recomendaciones del grupo GARIN para el tratamiento dietético de los pacientes con enfermedad renal crónica

MR Alhambra-Expósito, MJ Molina-Puerta… - Nutricion …, 2019 - SciELO Espana
Resultados: la actuación terapéutica debe ser individualizada y atendiendo al grado de
enfermedad renal que presente el paciente ya sus comorbilidades. En cuanto a la terapia …

磷酸盐保水机理及其对水产品保水作用的研究进展.

郭祉含, 王嵬, 贾志慧, 仪淑敏… - Journal of Food …, 2020 - search.ebscohost.com
磷酸盐是目前国内外应用最广泛的食品保水剂之一, 磷酸盐及其复配产品常应用在水产品加工
以及贮藏过程中, 以提高水产品的保水性, 最大限度减少水分, 风味物质及营养成分的流失 …